Literature DB >> 9076754

Direct activation of GABAA receptors by loreclezole, an anticonvulsant drug with selectivity for the beta-subunit.

E Sanna1, A Murgia, A Casula, M Usala, E Maciocco, G Tuligi, G Biggio.   

Abstract

Loreclezole, an anticonvulsant and antiepileptic compound, potentiates gamma-aminobutyric acid (GABA) type A receptor function, by interacting with a specific allosteric modulatory site on receptor beta-subunits. A similar selectivity for GABAA receptor beta-subunits is apparent for the direct activation of receptor-operated Cl- channels, by the general anesthetics propofol and pentobarbital. The ability of loreclezole to activate GABAA receptors directly has now been compared, biochemically and electrophysiologically, with that of propofol. In well-washed rat cortical membranes (devoid of endogenous GABA), loreclezole and propofol increased t-[35S]butylbicyclophosphorothionate ([35S]TBPS) binding by up to 28% (at 5 microM) and 80% (at 10 microM), respectively. Higher concentrations (50-100 microM) of both compounds inhibited [35S]TBPS binding with great efficacy, an effect mimicked by GABA. In contrast, the benzodiazepine diazepam increased [35S]TBPS binding, but failed to inhibit this parameter, even at high concentrations. At concentrations of 50-100 microM, loreclezole induced inward Cl- currents in the absence of GABA, in Xenopus oocytes expressing human recombinant GABAA receptors, comprised of alpha 1-, beta 2- and gamma 2S-subunits. At 100 microM, the current evoked by loreclezole was 26% of that induced by 5 microM GABA. The current evoked by 100 microM propofol was 98% of that induced by 5 microM GABA. Currents induced by loreclezole, like those evoked by propofol, were potentiated by diazepam in a flumazenil-sensitive manner and blocked by either bicuculline or picrotoxin. These data suggest that loreclezole shares, with propofol, an agonistic action at GABAA receptors containing the beta 2-subunit and that the different efficacies of the two compounds in this regard, may underlie the difference in their pharmacological profiles. The failure of loreclezole to activate GABAA receptors containing the beta 1-subunit may be responsible for its lack of hypnotic effect.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9076754     DOI: 10.1016/s0028-3908(96)00138-4

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  4 in total

1.  Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model.

Authors:  Jarogniew J Luszczki; Neville Ratnaraj; Philip N Patsalos; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-08       Impact factor: 3.000

2.  Esters of valerenic acid as potential prodrugs.

Authors:  Juliane Hintersteiner; Maximilian Haider; Denise Luger; Christoph Schwarzer; Gottfried Reznicek; Walter Jäger; Sophia Khom; Marko D Mihovilovic; Steffen Hering
Journal:  Eur J Pharmacol       Date:  2014-03-27       Impact factor: 5.195

3.  Molecular tools for GABAA receptors: High affinity ligands for β1-containing subtypes.

Authors:  Xenia Simeone; David C B Siebert; Konstantina Bampali; Zdravko Varagic; Marco Treven; Sabah Rehman; Jakob Pyszkowski; Raphael Holzinger; Friederike Steudle; Petra Scholze; Marko D Mihovilovic; Michael Schnürch; Margot Ernst
Journal:  Sci Rep       Date:  2017-07-18       Impact factor: 4.379

Review 4.  Allosteric GABAA Receptor Modulators-A Review on the Most Recent Heterocyclic Chemotypes and Their Synthetic Accessibility.

Authors:  Blanca Angelica Vega Alanis; Maria Teresa Iorio; Luca L Silva; Konstantina Bampali; Margot Ernst; Michael Schnürch; Marko D Mihovilovic
Journal:  Molecules       Date:  2020-02-24       Impact factor: 4.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.